Literature DB >> 32627907

Reported outcome measures for colorectal cancer patients during the COVID-19 pandemic.

T Tolley1, H McGregor1, J Clark1, M Worwood1, B M Stephenson1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32627907      PMCID: PMC7361929          DOI: 10.1111/codi.15236

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.917


× No keyword cloud information.
Dear Sir, The urgent reorganization of clinical services in response to the early stages of the COVID‐19 pandemic has had a significant impact on the delivery of colorectal cancer (CRC) surgery. Both patients and surgeons had difficult decisions to make, including individual risk assessment, issues pertaining to informed consent and the safety of laparoscopic surgery. We explored how our CRC patients felt they had been managed by way of a detailed postoperative telephone questionnaire. Patient‐reported outcome measures (PROMs) were based on the validated Functional Assessment of Cancer Therapy – Colorectal Cancer quality of life (QOL) survey [1, 2], adapted to specifically address the COVID‐19 situation. Patient details were accessed from the hospital’s electronic database. Over 9 weeks (17 March 2020 to 19 May 2020) we cautiously treated 21 CRC patients comprising 16 men and 5 women (median age 67.5 years, range 55–84 years). Nineteen patients underwent elective surgery (COVID‐19 screened) and two had emergency surgery. Three patients (14%) were diagnosed with COVID‐19 during admission, and there was one death. Overall median patient satisfaction score was 10/10 (range 3–10), but there was variation in QOL scoring dependent on the question subscale (Table 1).
Table 1

COVID‐19 quality of life survey outcomes.

QOL score subscalesMedianRange
Physical (0–12)94–11
Social (0–12)126–12
Emotional (0–12)73–10
Functional (0–12)108–12
COVID‐19: psychological impact (0–8)40–8
COVID‐19: practical impact (0–8)6.54–8
Overall QOL score (0–64)46.530–61
COVID‐19 quality of life survey outcomes. This PROM has given us insight into the clinical reality that these patients faced. Whilst overall satisfaction scores were high, additional attention needs to be focused on the emotional and psychological well‐being of future CRC patients should there be another wave of infection.

Conflicts of interest

None of the authors have any conflicting interest to declare.

Ethics and Service evaluation

No ethics committee review required.

Consent

All patients consented to data collection, analysis and dissemination.
  2 in total

1.  Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument.

Authors:  W L Ward; E A Hahn; F Mo; L Hernandez; D S Tulsky; D Cella
Journal:  Qual Life Res       Date:  1999-05       Impact factor: 4.147

Review 2.  Comparison of the FACT-C, EORTC QLQ-CR38, and QLQ-CR29 quality of life questionnaires for patients with colorectal cancer: a literature review.

Authors:  Vithusha Ganesh; Arnav Agarwal; Marko Popovic; David Cella; Rachel McDonald; Sherlyn Vuong; Henry Lam; Leigha Rowbottom; Stephanie Chan; Tasneem Barakat; Carlo DeAngelis; Michael Borean; Edward Chow; Andrew Bottomley
Journal:  Support Care Cancer       Date:  2016-05-18       Impact factor: 3.603

  2 in total
  1 in total

1.  Colorectal cancer in patients with SARS-CoV-2: a systematic review and meta-analysis.

Authors:  Saad Alhumaid; Abbas Al Mutair; Jawad S Busubaih; Nourah Al Dossary; Murtadha Alsuliman; Sarah A Baltyour; Ibrahim Alissa; Hassan I Al Hassar; Noor A Al Aithan; Hani A Albassri; Suliman A AlOmran; Raed M ALGhazal; Ahmed Busbaih; Nasser A Alsalem; Waseem Alagnam; Mohammed Y Alyousef; Abdulaziz U Alseffay; Hussain A Al Aish; Ali Aldiaram; Hisham A Al Eissa; Murtadha A Alhumaid; Ali N Bukhamseen; Koblan M Al Mutared; Abdullah H Aljwisim; Abdullah M Twibah; Meteab M AlSaeed; Hussien A Alkhalaf; Fatemah M ALShakhs; Thoyaja Koritala; Jaffar A Al-Tawfiq; Kuldeep Dhama; Ali A Rabaan; Awad Al-Omari
Journal:  Infect Agent Cancer       Date:  2022-09-12       Impact factor: 3.698

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.